Lead Sponsor

Gilead Sciences

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Willing and able to provide written informed consent
•HCV RNA ≥ 10\^4 IU/mL at screening
•Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy
•Any HCV genotype (1, 2, 3, 4, 5, 6 or indeterminate)
•HCV treatment-naive or treatment-experienced
•Liver imaging within 6 months of Day 1 is required in cirrhotic patients only to exclude hepatocellular carcinoma (HCC)

•Current or prior history of clinically-significant illness (other than HCV), gastrointestinal disorder, clinical hepatic decompensation, or post-operative condition that could interfere with the absorption of the study drug
•Pregnant or nursing female or male with pregnant female partner
•Chronic liver disease of a non HCV etiology
•Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)